Comment

Comment on FDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Disease | Landmark decision heralds a new type of medicine that can tackle genetic conditions that are hard to treat

<- View Parent

silence7@slrpnk.net ⁨1⁩ ⁨year⁩ ago

The pricing is higher than you’re describing - about 2 million dollars, which is still cheaper than paying for ongiong treatment over the course of a person’s life.

It’s priced to be attractive to corporate-sponsored insurance plans, not for individuals to pay out of pocket.

source

Sort:hotnew top

JohnDClay@sh.itjust.works ⁨1⁩ ⁨year⁩ ago
But the corporate sponsored insurance plans still need to be payed for somehow, usually as a deduction in what the company would pay since they can advertise better benefits. My friend’s family has sickle cell, but I guess this won’t help them since he’s a car salesman.

source
- silence7@slrpnk.net ⁨1⁩ ⁨year⁩ ago
  They pay for it by not having to cover the expense of treating the disease anymore. It’s an incredibly expensive disease to manage as a chronic condition.
  
  source
- threelonmusketeers@sh.itjust.works ⁨1⁩ ⁨year⁩ ago
  
  payed
  
  I think the word you’re looking for is “paid”. “Payed” is something to do with sailors and ropes or something.
  
  I am not a bot and this action was performed manually.
  
  source